Feed / XENE

Xenon Pharmaceuticals Inc.

XENE

Healthcare · 60.82 +1.9% today

Participation confirmed · construction unavailableMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Xenon Pharmaceuticals Inc.'s move is being confirmed by its market group.

The latest filing evidence is available. 10 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

What changed
  • The operating loss widened by 28.9M.
Company+1.9% todayVolume comparison unavailable
Market group10 of 16 activeClinical Biopharmaceuticals · inactive
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind XENE

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

NBIXNeurocrine Biosciences, Inc.partnerMay 7, 2026

Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.

JAZZJazz Pharmaceuticals plccompetitorFeb 26, 2026

There are other ASMs in development that could potentially compete with our products, including product candidates in development from Biohaven Ltd., Jazz Pharmaceuticals, plc, Neurona Therapeutics Inc., NeuShen Therapeutics, Inc., Otsuka Pharmaceutical Co.

Depended on by

NBIXNeurocrine Biosciences, Inc.partnerFeb 11, 2026

Some of our other collaborators include Nxera Pharma UK Limited (formerly Sosei Heptares), Takeda Pharmaceutical Company Limited, Voyager Therapeutics, Inc., and Xenon Pharmaceuticals Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

XENE is currently a Early Follower in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.